Anti-SARS-CoV-2 IgA Response in Baseline Seronegative and Seropositive Recipients of BNT162b2 mRNA COVID-19 Vaccine

J Occup Environ Med. 2021 Nov 1;63(11):e829. doi: 10.1097/JOM.0000000000002362.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • BNT162 Vaccine
  • COVID-19 Vaccines*
  • COVID-19*
  • Humans
  • Immunoglobulin A
  • RNA, Messenger
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines
  • Immunoglobulin A
  • RNA, Messenger
  • BNT162 Vaccine